anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a composition having excellent durability of adhesion to noble metals and noble metal alloys by compounding a sulfur compound having a sulfur residue and/or a salt thereof, a silane coupling agent bearing a polymerizable group, and a solvent and/or a polymerizable monomer. SOLUTION: A sulfur compound and its salt have a polymerizable group and a sulfur residue exhibiting excellent adhesive properties to a noble metal (gold in particular), and there can be exemplified, for example, a compound represented by formula I, and the like. A silane coupling agent contains a polymerizable group such as a (meth)acryloyl group or the like in the molecule, and there can be exemplified, for example, a compound represented by formula II, wherein Q is O, S or NH; q is 2-20; and R is a halogen or an alkoxy, and the like. As a solvent, is employed, for example, a volatile organic solvent having a boiling point at ordinary pressure of 250 deg.C or lower (e.g. ethanol), water or a mixture thereof. As a polymerizable monomer, is employed usually a monomer, for example, α-cyanoacrylic acid or the like.
PURPOSE:To obtain a novel thrombin binding substance useful for remedying thrombosis, by extracting ground human placenta with a buffer solution containing a nonionic surface active agent and separating the substance by various kinds of chromatography, etc. CONSTITUTION:Ground human placenta is extracted with a buffer solution containing a nonionic surface active agent and a fraction separated by ion exchange chromatogrphy, affinity chromatography using thrombin-carrier bonded material and/or gel filtration from the extract is subjected to molecular weight fractionation to give a novel thrombin binding substance having the following properties. Molecular weight: 47,000+ or -6,000 (reduced state) and 38,000+ or -6,000 (nonreduded state). Affinity: having storing affinity for thrombin. Activity: bonded to thrombin to activate protein C and to prolong coagulation time of blood. Consequently, the substance is useful as a fibrinolysis promotor and an anticoagulant.
Microbial drug resistance is an unavoidable consequence resulting from abuse and overuse of antimicrobial agents. Given the degree of popularity of β-lactam antibiotics, it is not surprising that the prevalence of β-lactamase-producing strains is increasing worldwide. β-lactamases are able to hydrolyze the β-lactam antibiotics resulting in the loss of antibacterial activity. The present invention addresses this problem by providing compounds that inhibit some of the β-lactamase enzymatic function either alone or in synergy with other β-lactam antibiotics, increasing the potency of β-lactam antibiotics. In particular, the present invention provides a compound of formula (I) wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds are disclosed.
BACKGROUND: Sternotomy wound complications are more frequent after orthotopic heart transplantation (OHT) compared to other cardiac surgeries, primarily due to additional risk factors, including immunosuppression. Flap closure often becomes necessary for definitive treatment, although there is a scarcity of data on the outcomes of sternal wound reconstruction in this specific population.
METHODS: A retrospective analysis was conducted on 604 sternal wound reconstructions performed by a single surgeon between 1996 and 2023. Inclusion criteria comprised patients who underwent OHT as their primary cardiac procedure. Surgical interventions involved sternal hardware removal, debridement, and muscle flap closure.
RESULTS: The study included 66 patients, with culture-positive wound infection being the most common indication for reconstruction (51.5%). The median duration between transplantation and sternal wound reconstruction was 25 days. Bilateral pectoralis major myocutaneous advancement flaps (n = 63), rectus abdominis flaps (n = 2), or pectoralis major turnover flaps (n = 1) were used. Intraoperative wound cultures revealed positivity in 48 patients (72.7%), with Staphylococcus epidermidis being the most frequently cultured organism (25.0%). The overall complication rate was 31.8%, and two patient deaths were related to sternal wounds, resulting from multiorgan failure following septic shock. The majority of the patients reported excellent long-term functional and esthetic outcomes.
CONCLUSIONS: Sternal wounds following OHT pose a significant morbidity risk. Our strategy focuses on immediate and aggressive antibiotic therapy, thorough debridement, and definitive closure with bilateral pectoralis myocutaneous advancement flaps. This approach has demonstrated complication and mortality rates comparable to the general cardiac surgery population, as well as excellent functional and esthetic results.
NEW MATERIAL:Naphthalene derivatives of the formula (wherein R is H or chlorine). USE:The title derivatives which are useful as vat dyes for fibers and human hair dyes, has excellent stability, can be oxidized in baths without using specific oxidizing agents to develop color and are suitable for use as dyes which dye fibers dark brown, as pigments and intermediates for dyes and pigments. PREPARATION:2-Substd. anilino-5,8-dihydroxynaphthoquinone is reduced in the presence of SnCl2 (1) by using a reducing agent such as sodium dithionate in water and/or an alcohol at room temp. to refluxing temp. for 10min-3hr, or (2) by using zinc in an aq. hydrochloric acid soln. at room temp. to refluxing temp. for 10min-3hr.
An argon arc welding synchronous automatic control eye protector relates to a device for eye protection in argon arc welding, in particular to an eye protector capable of moving the screening glasses automatically and working with the argon arc welding synchronously. The convex part of a cam track is clamped into the grooves of concave wheels at four corners of the screening glasses connected with a rack which is meshed with a gear of a motor and provided with a magnet at the upper end. The motor is respectively connected with a magnetic-controlled switch 1TJ, 2TJ of the magnet and a relay 1SJ [2], the 1TJ and 2TJ are connected with a relay 1SJ [1], and the power is connected with an argon arc welding switch K, a relay 1SJ and a relay 2SJ. The utility model drives the rack to move upward by the gear on the motor. When the upper magnet reaches the magnetic-controlled switch 1TJ, the motor will stop working. Then the staff starts the argon arc welding switch aiming at the welding point to make the rack move downward. When the magnet reaches the magnetic-controlled switch 2TJ, the motor will stop working and the argon arc welding will start working. The utility model has simple structure, convenient operation, high working efficiency, good welding quality and effective protection of eyes from arc light injury.
The invention discloses a Tibetan medicine composition. Aiming at the defect that most products for preventing and treating alcoholic liver diseases have obvious side effects in the prior art, the invention discloses a Tibetan medicine composition and application of the composition in preparation of products for preventing and treating the alcoholic liver diseases. The Tibetan medicine composition comprises the following components in parts by weight: 25 to 75 parts of fructus chebulae, 15 to 45 parts of rhodiola sachalinensis, 20 to 60 parts of flos carthami, 20 to 60 parts of dandelion and 10 to 30 parts of lucid ganoderma. The components of the Tibetan medicine composition as the composition are applied to the preparation of medicaments for preventing and treating the alcoholic liver diseases for the first time, the different components brings the effects into play so as to achieve an aim of preventing and treating the alcoholic liver diseases in multiple aspects of removing focus, protecting the liver and nourishing and strengthening the body. The Tibetan medicine composition provided by the invention as an effective component can be applied to preparation of the products for preventing and treating the alcoholic liver diseases, including either the medicaments for preventing and treating the alcoholic liver diseases or health care products for preventing and treating the alcoholic liver diseases. Original medicine components of the Tibetan medicine composition are few, the production cost is cheap, a preparation method is simple, and medicinal material original medicines and the preparation method are safe and reliable.
In systemic sclerosis (SSc), fibrosis of the myocardium along with ongoing autoimmune inflammation can alter the electric function of the cardiac myocytes, which may increase the risk for ventricular arrhythmias and sudden cardiac death. We analyzed the electrocardiographic (ECG) variables describing ventricular repolarization such as QT interval, QT dispersion (QTd), T wave peak-to-end interval (Tpe), and arrhythmogeneity index (AIX) of 26 patients with SSc and 36 healthy controls. Furthermore, echocardiographic and laboratory parameters were examined, with a focus on inflammatory proteins like C-reactive ptotein (CRP), soluble intracellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), and progranulin (PGRN). The CRP, sICAM-1, and sVCAM-1 levels were positively correlated with the length of the QT interval. Although the serum PGRN levels were not increased in the SSc group compared to the controls, in SSc patients, the PGRN levels were positively correlated with the QT interval and the AIX. According to our results, we conclude that there may be a potential association between autoimmune inflammation and the risk for ventricular arrhythmias in patients with SSc. We emphasize that the measurement of laboratory parameters of inflammatory activity including CRP, PGRN, sVCAM-1, and sICAM-1 could be helpful in the prediction of sudden cardiac death in patients with SSc.
This research is designed to test the efficacy of a computer based virtual simulation for teaching ear surgery. Subjects will be randomized to training in the usual fashion and training in the simulation environment. Subjects performance will be tested in a standard fashion by dissecting cadaveric temporal bones (human ears) before and after training. The subjects will also perform a dissection in the virtual environment before and after training. The results will be tabulated to compare the different training arms. There is minimal risk associated with the projects and is limited to exposure to cadaveric material. Current training techniques utilize cadaveric material so exposure to this type of material is already a part of the standard training process and this study should not constitute an increased risk beyond what is encountered during their regular training. Demographic information will be obtained for each of the study subject on age, sex, information regarding previous otologic training, year of training and prior experience using computers. The anticipated benefits to society will be that future otologic surgeons can obtain operative experience in a controlled and non threatening environment. They will have access to a greater number of variations in pathology. This will allow each novice surgeon to obtain significantly more experience outside the operating room prior to working with live patients. This will result in less risk to the patient and better trained ear surgeons.
310,934. Zipf, K. E. May 3, 1938, [Convention date]. Void [Published under Sect. 91 of the Acts]. Medicines for internal use.-Preparations of insulin suitable to be administered by the mouth are obtained by mixing insulin, or organs or preparations of organs containing it, with an organic acid, or a salt thereof, or an agent yielding acid or splitting off formaldehyde, or a mixture of such substances. The preparations are put up in hardened gelatine capsules or as coated pills so as to be protected against gastric digestion. Acids specified are the fatty acids, and benzoic, hippuric, methylene hippuric, glutaric, glutaminic, mandelic, and cinnamic acids; agents yielding acids are acid esters and acid amides such as fats and formamide: agents yielding formaldehyde are methylene hippuric acid, hexamethylene tetramine, methylene citric acid, para-formaldehyde, and trioxymethylene. According to examples dry insulin is mixed respectively with (1) hippuric acid and sodium hippurate, (2) methylene hippuric acid, and (3) benzoic acid, para-formaldehyde, sodium hippurate, and glutaminic acid. The prior use of mixtures of insulin with inorganic acid is referred to.
The invention comprises a composition for relieving pain and promoting healing in the treatment of post extraction alveolitis, or dry socket, following tooth extraction. My formulation comprises procaine, charcoal, balsam of Peru, creosote, kaolin, and eugenol. It possesses the distinctive property of remaining plastic indefinitely after application and requires no irritating carriers, such as gauze. It also has the desirable characteristic of remaining in place until the tooth socket is covered by granulation tissue. As the tooth socket heals, my formulation disappears substantially to the same extent, until when healing is complete the compound of my invention has completely disappeared. My invention does not reside in the use of any particular ingredient, all of which were known for the same or similar uses, but in the formulation of all of the ingredients in such a manner as to create a soft plastic mass which is nonhardening.
Single site, double blinded, placebo controlled randomized clinical trial. 40 subjects will be selected based on the inclusion criteria and then randomized to either the intervention group or the placebo control group. Prior to the start of this study, a Controlled Substance Utilization Review and Evaluation (CURES) reports will be acquired to establish baseline number of opioid prescriptions for each subject. Subjects will track how consistently they are using pain medications, both opioids and non-opioids, during the two weeks prior to the start of the study. They will also provide twice daily recordings of their pain intensity via a mobile application. At the end of this two-week period, each subject will be fitted with a Quell device or a sham device, including initial calibration to the subject's comfort level as described in the background section.Once the study subjects have started using the device, we will also be able to monitor and track their sleep wirelessly via the mobile application as long as they are wearing the device. Subjects will receive weekly check in's to monitor the functionality of the device and to help troubleshoot any issues with the device for the duration of subject participation in the study. These check-ins will take place in person, by phone, and or per subject's usual outpatient oncology visits. Each subject will use their device for 8 weeks, during which they will continue to track their pain, sleep and frequency of pain medication use as stated above. Study investigators will receive automated alerts via email to ensure that study are participants using their devices and that the devices are powered on at regular intervals for the duration of the study.Total duration of subject participation will be 10 weeks.
BACKGROUND: Mutations in the receptor tyrosine kinase KIT are the main cause of gastrointestinal stromal tumor (GIST), and the KIT mutants mediated PI3 kinase activation plays a key role in the tumorigenesis of GIST. In this study, we aimed to block PI3 kinase activation by cell-permeable peptide and investigate its possible application in the treatment of GIST.
METHODS AND RESULTS: We designed cell-permeable peptides based on the binding domain of PI3 kinase subunit p85 to KIT or PI3 kinase subunit p110, respectively, in order to compete for the binding between p85 and KIT or p110 and therefore inhibit the activation of PI3 kinases mediated by KIT. The results showed that the peptide can penetrate the cells, and inhibit the activation of PI3 kinases, leading to reduced cell survival and cell proliferation mediated by KIT mutants in vitro. Treatment of mice carrying germline KIT/V558A mutation, which can develop GIST, with the peptide that can compete for the binding between p85 and p110, led to reduced tumorigenesis of GIST. The peptide can further enhance the inhibition of the tumor growth by imatinib which is used as the first line targeted therapy of GIST.
CONCLUSIONS: Our results showed that cell-permeable PI3 kinase competitive peptide can inhibit KIT-mediated PI3 kinase activation and tumorigenesis of GIST, providing a rationale to further test the peptide in the treatment of GIST and even other tumors with over-activation of PI3 kinases.
Punicic acid (PA), mainly found in pomegranate seed oil (PSO), has attracted increasing attention due to its potential to mitigate obesity. The regulation of intestinal microflora was identified as a crucial factor and an effective strategy to reverse obesity-related hyperlipidemia and non-alcoholic fatty liver disease (NAFLD). To assess the impact of PSO on hyperlipidemia related to obesity, we investigated the hepatic lipid status and gut microbiota regulation in mice over 13 weeks of feeding a high-fructose high-fat diet (HFHFD). Serum lipid markers, including TG, TC and LDL-C, were markedly reduced in hyperlipidemic mice. PSO supplementation reduced hepatic lipid accumulation and steatosis, inhibited the expression of pro-inflammatory mediators (including IL-6 and IL-1β), and restored the normal levels of the anti-inflammatory cytokine IL-10. In addition, PSO also alleviated oxidative stress and increased T-AOC and SOD activities, as well as GSH levels, while reducing the MDA content in the liver of HFHFD-fed mice. The activation of TLR4/MyD88/NF-κB and TLR4/IL-22/STAT3 signaling pathways in the liver due to the HFHFD was also evidently inhibited by PSO. Furthermore, supplementation of PSO ameliorated the HFHFD-induced dysbiosis of intestinal microflora, resulting in a markedly increased proportion of Muribaculaceae, a decreased ratio of Blautia, and elevated levels of microbiota-derived short-chain fatty acids (SCFAs). Moreover, the expression of tight junction proteins correlated with intestinal barrier function was notably restored in the colon. The collected results indicate that PSO may be an effective nutraceutical ingredient for attenuating lipid metabolic disorders.
Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
There is a strong association between smoking and schizophrenia with prevalence rates ranging from 74% to 90%, versus a national average of 30% in nonschizophrenic individuals. A number of hypotheses have been proposed to explain the relationship between high smoking rates and schizophrenia, mostly relating to self-medication primarily for the negative symptoms of schizophrenia. Smoking cessation rates among schizophrenic patients are considerably lower than for other psychiatric disorders. The negative health effects of smoking increase the morbidity and mortality in schizophrenic patients. The smoking cessation agent bupropion HCl has been tested in schizophrenics, but the results on its efficacy are inconclusive. Recent works by different laboratories have shown the safety and efficacy of varenicline, a partial alpha4beta2 and full alpha7 nicotinic acetylcholine receptor agonist, as a smoking cessation agent. However, to date, no published studies have tested the safety and efficacy of varenicline in treatment of nicotine dependence in schizophrenic patients. As varenicline appears to be a promising treatment in non-psychiatric patients, it would be beneficial to examine its effects in schizophrenic patients. The central hypothesis of this application is that treatment with varenicline will safely increase smoking abstinence rates in schizophrenic patients when compared to those receiving placebo. This central hypothesis will be tested and the objectives of this application accomplished by pursuing two Specific Aims: 1) Treatment with varenicline or bupropion HCl for a period of three months will increase smoking abstinence rates in schizophrenic patents when compared to placebo; and 2) Treatment with varenicline or bupropion HCl for a period of three months will not increase psychosis in schizophrenic patients when compared to placebo. For our General Investigational Plan, we will employ a double-blind randomized placebo controlled study to assess varenicline's safety and efficacy. It is our expectation that we will demonstrate that varenicline is safe and effective in decreasing smoking rates in schizophrenic patients without exacerbating psychotic symptoms. Such outcomes will be significant, because they will offer a new treatment for smoking cessation in this vulnerable population.
Participants are given the same anti-rejection therapy as the control group after liver transplantation. 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mgor 12 mg orally once a day. The initial dose was 8 mgor 12 mg orally once a day.
This study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. The goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders. Individuals between the ages of 18-65 with elevated fear of spiders or fear of snakes are randomly assigned to one of four treatment conditions (1) standard exposure therapy, (2) exposure therapy with fear retrieval augmentation, (3) exposure therapy with compound extinction augmentation, and (4) exposure therapy with fear retrieval and compound extinction augmentations. All participants undergo an online prescreen and a face-to-face screening assessment to determine eligibility and baseline (pre-treatment) symptom severity. Participants additionally complete assessments directly after treatment (post-treatment), and approximately one week after treatment (follow-up). The pre-treatment assessment occurs 1-14 days prior to treatment, the post-treatment assessment occurs during the treatment visit as soon as the treatment procedure is complete, and the follow-up assessment occurs within a window of 6-14 days after the completion of treatment. Participants complete two behavioral approach tests (in the treatment context and in the generalization context) at pre-treatment, post-treatment, and follow-up. Participants complete a battery of self-report questionnaires at pre-treatment and follow-up.
Fifty subjects are to be enrolled retrospectively from the medical records of breast cancer patients who have undergone breast reconstruction surgery based on inserting breast implants with ADM made by other companies. All breast reconstruction surgeries have operated from 1, June 2021 to 9, November 2021 at Asan medical center at Seoul, South Korea.